Logo

MDWD

MediWound Ltd.

MDWD

MediWound Ltd. • NASDAQ
$17.92 ▼ -0.39% (-0.07)
Market Cap $194.66 M
52w High $22.50
52w Low $14.14
Dividend Yield 0%
P/E -9.74
Volume 41.99K
Outstanding Shares 10.86M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $5.429M ▼ $7.421M ▲ $-2.652M ▲ -48.849% ▲ $-0.24 ▲ $-2.181M ▲
Q2-2025 $5.708M ▲ $7.058M ▲ $-13.318M ▼ -233.322% ▼ $-1.23 ▼ $-4.893M ▼
Q1-2025 $3.955M ▼ $5.959M ▼ $-726K ▲ -18.357% ▲ $-0.07 ▲ $-363K ▲
Q4-2024 $5.84M ▲ $6.986M ▲ $-3.908M ▲ -66.918% ▲ $-0.36 ▲ $-3.493M ▲
Q3-2024 $4.355M $5.758M $-10.282M -236.096% $-0.98 $-4.72M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $59.09M ▲ $94.423M ▲ $34.981M ▼ $50.156M ▲
Q2-2025 $32.436M ▼ $67.001M ▼ $46.882M ▲ $20.119M ▼
Q1-2025 $38.266M ▲ $69.016M ▼ $37.744M ▼ $31.272M ▲
Q4-2024 $9.155M ▼ $73.496M ▼ $42.343M ▲ $31.153M ▼
Q3-2024 $45.562M $74.734M $40.499M $34.235M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-2.652M ▲ $-2.595M ▲ $3.726M ▼ $31.931M ▲ $58.031M ▲ $-3.703M ▲
Q2-2025 $-13.318M ▼ $-5.756M ▼ $4.905M ▲ $549K ▲ $-300K ▲ $-6.805M ▼
Q1-2025 $-726K ▲ $-4.11M ▼ $-3.343M ▼ $-362K ▲ $-7.796M ▼ $-5.069M ▼
Q4-2024 $-3.908M ▲ $-1.637M ▲ $4.828M ▲ $-513K ▼ $2.68M ▼ $-2.443M ▲
Q3-2024 $-10.282M $-3.756M $-14.286M $20.709M $2.685M $-4.948M

Five-Year Company Overview

Income Statement

Income Statement MediWound looks like a classic early-stage biotech: commercially active but not yet financially mature. Revenue is still very small and has not yet ramped in a meaningful way. Gross profit exists but is thin, and operating results remain firmly in the red. Losses have persisted for several years, and the most recent year shows a step down in earnings compared with the prior year. In practical terms, the business is still in investment mode, with R&D and commercial build-out outweighing the revenue it generates from NexoBrid and other activities.

Balance Sheet

Balance Sheet The balance sheet is relatively simple and light. Total assets have grown modestly, with a reasonable base of equity and only a small layer of debt. Cash on hand is not large, especially when viewed against ongoing operating losses, which means financial flexibility is not unlimited. On the positive side, leverage appears low, so the company is not heavily burdened by debt. The key question over time will be access to capital—through partnerships, grants, or equity—if losses continue at a similar pace.

Cash Flow

Cash Flow Cash flow from operations has been consistently negative, reflecting a business that spends more on development, overhead, and commercialization than it brings in from product sales and collaborations. Free cash flow is even more negative because of investment in equipment and facilities, likely tied to manufacturing expansion and future growth plans. This pattern is typical for a biotech scaling up, but it means the company depends on external funding sources and successful partnerships to sustain its research and commercialization efforts.

Competitive Edge

Competitive Edge MediWound occupies a specialized corner of wound care, with enzymatic products that aim to replace or reduce surgical removal of dead tissue. Its flagship burn product, NexoBrid, is approved in many major markets, which gives it real-world validation and a head start. The company’s technology is protected by patents and know-how, and it controls much of its manufacturing chain, adding to its defensibility. Strategic alliances with larger wound-care and biotech partners extend its commercial reach, especially in the U.S. and key global markets. The flip side is that MediWound is still a small player surrounded by larger, well-funded competitors, and its current commercial success is concentrated in a narrow set of indications, which heightens dependence on a few core products.

Innovation and R&D

Innovation and R&D R&D is clearly the heart of the story. MediWound’s enzyme platform underpins several product lines: an approved burn therapy (NexoBrid), an advanced chronic wound candidate (EscharEx) in late-stage trials, and an early oncology-related program (MW005) for common skin cancers. Clinical data so far suggest meaningful advantages in speed and completeness of debridement versus existing non-surgical options, which, if confirmed in larger trials, could open up sizable markets in chronic wounds. The company is also investing in manufacturing expansion to support potential growth. However, late-stage trials are inherently risky, timelines stretch over years, and success is not guaranteed. Continued progress will require sustained funding, smooth regulatory interactions, and the ability to translate clinical performance into broad clinical adoption.

Summary

Overall, MediWound is an innovation-driven, niche biotech with a differentiated technology platform and one commercialized product that provides proof of concept. Financially, it is still in the loss-making, cash-burning phase, with modest resources and limited room for prolonged setbacks without fresh capital. Strategically, its strength lies in specialized know-how, regulatory approvals across many countries, and strong partnerships that extend its reach beyond what its size would normally allow. The future trajectory will largely hinge on three factors: how quickly and broadly NexoBrid can grow, whether EscharEx and MW005 succeed in late-stage development and approval, and how effectively the company manages funding needs and competitive pressures over the next several years.

NEWS

November 20, 2025 · 7:00 AM UTC

MediWound Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Read more

November 5, 2025 · 7:30 AM UTC

MediWound to Report Third Quarter 2025 Financial Results

Read more

November 3, 2025 · 8:00 AM UTC

MediWound Successfully Completes Commissioning of Expanded GMP Manufacturing Facility for NexoBrid®

Read more

September 29, 2025 · 8:37 AM UTC

MediWound Announces $30 Million Registered Direct Offering of Ordinary Shares

Read more

September 25, 2025 · 7:30 AM UTC

MediWound Expands Global Reach with Marketing Approval of NexoBrid® in Australia

Read more